I think we are now in the final phase of this impo
Post# of 157649
(Total Views: 684)
Posted On: 08/15/2025 11:16:24 AM
I think we are now in the final phase of this important message from our CEO:
Phase 1
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center.
Phase 2
We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors.
Phase 3
The Company intends to use this preclinical study to form the basis for a potential partnership and better inform the design of a follow-up clinical study in patients with metastatic TNBC.
I strongly believe our management team is in the process of finalizing a partnership for TNBC. It is probably tied to the early analysis of our current cancer trial, but I think that the TNBC partnership will happen no matter what the current cancer trial data shows.
Phase 1
I am pleased to announce that CytoDyn is working with a team of experts to resume the exploration of Triple-Negative Breast Cancer (“TNBC”), including colleagues from the University of Hawaii Cancer Center, MD Anderson Cancer Center, and the Pennsylvania Cancer and Regenerative Medicine Research Center.
Phase 2
We will be working with this team in the coming months to design and conduct a preclinical TNBC study that will aim to confirm the mechanism of action of leronlimab in oncology and address the question of potential synergies with both antibody-drug conjugates and immune checkpoint inhibitors.
Phase 3
The Company intends to use this preclinical study to form the basis for a potential partnership and better inform the design of a follow-up clinical study in patients with metastatic TNBC.
I strongly believe our management team is in the process of finalizing a partnership for TNBC. It is probably tied to the early analysis of our current cancer trial, but I think that the TNBC partnership will happen no matter what the current cancer trial data shows.
(21)
(0)